22(S)-hydroxy Cholesterol – 5 mg

Brand:
Cayman
CAS:
22348-64-7
Storage:
-20
UN-No:
Non-Hazardous - /

22(S)-hydroxy Cholesterol is a synthetic oxysterol and a modulator of the liver X receptor (LXR).{41628} It prevents monocyte chemoattractant protein 1 (MCP-1) expression induced by the LXR agonist GW 3965 (Item No. 10054) in primary hepatocytes and downregulates mRNA expression of the LXR target genes CD36, ACSL1, and SCD-1 in human myotubes.{41629} It decreases triacylglycerol and diacylglycerol synthesis from labeled palmitate and acetate, respectively, in human myoblasts by 50% when used at a concentration of 10 µM.{41628} 22(S)-hydroxy Cholesterol also reduces fatty acid synthase (FASN) reporter activity through an LXR response element in the promoter region in COS-1 cells transfected with RXRα and LXRα and decreases the expression of MCP-1 and CCR2 in a mouse model of chronic ethanol consumption.{41628,41629} Dietary supplementation of 22(S)-hydroxy cholesterol (30 mg/kg per day) leads to less body weight gain and lower liver triacylglycerol levels in rats when fed either a regular chow or high-fat diet as well as prevents an increase in plasma triacylglycerol levels resulting from a high-fat diet.{41630}  

 

Out of stock

SKU: 21399 - Category:

Description

A synthetic oxysterol and LXR modulator; decreases triacylglycerol and diacylglycerol synthesis from labeled palmitate and acetate, respectively, in human myoblasts by 50% (10 µM); reduces FASN reporter activity through an LXR response element in the promoter region in COS-1 cells; dietary supplementation leads to less body weight gain and lower liver triacylglycerol levels in rats fed regular chow or a high-fat diet (30 mg/kg per day)


Formal name: cholest-5-ene-3β,22S-diol

Synonyms:  22β-hydroxy Cholesterol

Molecular weight: 402.7

CAS: 22348-64-7

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Lipids|Sterol Lipids||Product Type|Biochemicals|Receptor Pharmacology|Allosteric Modulators||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Endocrinology & Metabolism|Hormones & Receptors|FXRs & LXRs||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity||Research Area|Lipid Biochemistry|Glycerolipids||Research Area|Lipid Biochemistry|Sterol Lipids